{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:43:42Z","timestamp":1692053022985},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Solithromycin is a fourth-generation macrolide antibiotic with potential efficacy in pediatric community-acquired bacterial pneumonia. Pharmacokinetic (PK) studies of solithromycin in pediatric subjects are limited, therefore application of minimally invasive drug sampling techniques, such as dried blood spots (DBS), may enhance the enrollment of children in PK studies. The objectives of this study were to compare solithromycin concentrations in DBS with those in liquid plasma samples (LPS) and to quantify the effects of modeling DBS concentrations on the results of a population PK model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Comparability analysis was performed on matched DBS and LPS solithromycin concentrations collected from two different phase 1 clinical trials of solithromycin treatment in children (clinicaltrials.gov #NCT01966055 and #NCT02268279). Comparability of solithromycin concentrations was evaluated based on DBS:LPS ratio, median percentage prediction error, and median absolute percentage prediction error. The effect of correcting DBS concentrations for both hematocrit and protein binding was investigated. In addition, a previously published population PK model (NONMEM<jats:sup>\u00ae<\/jats:sup>) was leveraged to compare parameter estimates resulting from either DBS or LPS concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 672 paired DBS-LPS concentrations were available from 95 subjects (age: 0\u201317 years of age). The median (range) LPS and DBS solithromycin concentrations were 0.3 (0.01\u201312) mcg\/mL and 0.32 (0.01\u201314) mcg\/mL, respectively. Median percentage prediction error and median absolute percentage prediction error of raw DBS to LPS solithromycin concentrations were 5.26% and 22.95%, respectively. In addition, the majority of population PK parameter estimates resulting from modeling DBS concentrations were within 15% of those obtained from modeling LPS concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Solithromycin concentrations in DBS were similar to those measured in LPS and did not require correction for hematocrit or protein binding.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000670","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T08:41:02Z","timestamp":1563439262000},"page":"761-765","source":"Crossref","is-referenced-by-count":1,"title":["A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication"],"prefix":"10.1097","volume":"41","author":[{"given":"Ryan J.","family":"Beechinor","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University Medical Center, Durham;"},{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Jasion","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University Medical Center, Durham;"},{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University Medical Center, Durham;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Chapel Hill, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1208\/s12248-014-9695-3","article-title":"Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ consortium microsampling working group","volume":"17","author":"Evans","year":"2015","journal-title":"AAPS J."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpba.2016.06.026","article-title":"Clinical feasibility of dried blood spots: analytics, validation, and applications","volume":"130","author":"Enderle","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijabmr.IJABMR_7_18","article-title":"Applications and diagnostic potential of dried blood spots","volume":"8","author":"Gupta","year":"2018","journal-title":"Int J App Basic Med Res."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-015-9860-3","article-title":"An integrated strategy for implementation of dried blood spots in clinical development programs","volume":"18","author":"Kothare","year":"2016","journal-title":"AAPS J."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","article-title":"Innovative clinical trial design for pediatric therapeutics","volume":"4","author":"Laughon","year":"2011","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.4155\/bio.13.156","article-title":"Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions","volume":"5","author":"De Kesel","year":"2013","journal-title":"Bioanalysis."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.2147\/DDDT.S119545","article-title":"Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy","volume":"11","author":"Donald","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2146\/ajhp160934","article-title":"Solithromycin: a novel ketolide antibiotic","volume":"74","author":"Buege","year":"2017","journal-title":"Am J Health Syst Pharm."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-016-0667-z","article-title":"Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00692-18","article-title":"Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents","volume":"62","author":"Gonzalez","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1128\/AAC.02561-15","article-title":"Solithromycin pharmacokinetics in plasma and dried blood spots and safety in adolescents","volume":"60","author":"Gonzalez","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.04652-14","article-title":"Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment","volume":"59","author":"Jamieson","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/INF.0b013e3182947cf8","article-title":"Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants","volume":"32","author":"Cohen-Wolkowiez","year":"2013","journal-title":"Pediatr Infect Dis J."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:14:47Z","timestamp":1692051287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000670","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}